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There is an increasing interest in studying the role of GABAergic medications 
in the treatment of alcohol dependence. The GABAergic drug gamma- 
hydroxybutyric acid (GHB) has been investigated in Europe as a possible 
treatment for alcohol dependence. In some European Countries, GHB has 
been approved as a treatment for alcohol dependence. However, this drug 
has also shown addictive properties, therefore raising questions about its 
safety in treating alcohol-dependent subjects. More recent research is focusing 
on the possibility of identifying alcohol-dependent subtypes without risk of 
developing GHB abuse. Finally, GHB and naltrexone combined together 
represent a possible approach deserving future investigations.
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1.	 Introduction
1.1	 Alcohol	dependence
Alcohol dependence is a chronic disease with a multifactorial etiology and is 
characterized by excessive drinking, alcohol craving, loss of control, tolerance and 
physical dependence  [1]. Chronic alcohol consumption is able to affect the brain, 
altering its neurochemical properties. These long-lasting changes in the brain are 
supposed to be based on the neurobiology of alcohol dependence  [2]. Alcohol 
affects virtually all neurotransmitter or neuromodulator systems, either directly or 
indirectly  [2]. Long-term exposure to alcohol causes adaptive changes in several 
neurotransmitter systems, including gamma-aminobutyric acid (GABA) receptors, 
glutamate receptors and central norepinephrine activity  [3]. Alcohol enhances the 
inhibitory GABAergic transmission, mainly via a potentiation of the GABAA 
receptor function and possibly through an indirect increase in GABA release  [4]. 
Alcohol also inhibits the excitatory glutamatergic transmission through its action 
on glutamate receptors  [5]. In addition to glutamate and GABA receptors, alcohol 
has also shown to interact with several other neurotransmitter receptors such as 
serotonin, glycine and nicotinic acetylcholine receptors  [6-8]. Additionally, alcohol 
induces presynaptic changes in neurotransmitter release, in particular stimulating 
dopamine release in the ventral striatum/nucleus accumbens area  [9-11].
1.2	 Pharmacological	treatment	of	alcohol	dependence
The advances in the field of neuroscience have contributed significantly to 
developing the rationale for investigating pharmacological compounds, as part of 
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the clinical management of alcohol-dependent subjects. In fact, 
the concomitant use of pharmacological and psychological 
approaches could produce an additive effect in the control 
of the compulsive desire for alcohol and in maintaining 
alcohol abstinence  [12]. As a consequence, several medica-
tions have been investigated as a treatment for alcohol 
dependence  [13-16]. In particular, while disulfiram has been 
used for several decades, more recently three new treatments 
(oral and long-acting intramuscular naltrexone, and acamp-
rosate) have received regulatory approval for alcohol dependence 
in the USA. Unlike disulfiram, these compounds target 
neurobiological processes that are thought to be involved in 
the pathophysiology of alcohol dependence. Naltrexone is 
widely used in the USA, in Australia and in several European 
countries but, for example, is not licensed in the UK. 
Acamprosate has been used for years in Europe, but it was 
approved in the USA only in 2004. Furthermore, the general 
perception is that the overall efficacy is modest, despite the 
fact that some patients have profound responses to these 
medications. Also, there is no agreement as to whether the 
combination of these medications (e.g., naltrexone and 
acamprosate) might be better than either drug alone  [17]. 
Therefore, there is a substantial need for discovering innovative 
ways to provide effective pharmacotherapy for alcohol depen-
dence. Among new possible neuropharmacological targets in 
treating alcohol dependence, there is an increasing interest 
in studying medications working on the GABA system, such 
as topiramate, baclofen, gabapentin and gamma-hydroxybutyric 
acid (GHB)  [18].
The GABAergic compound GHB has been investigated 
in Europe as a possible treatment for alcohol dependence. 
The present review summarizes the clinical studies testing 
GHB in the treatment of alcohol dependence. Although GHB 
has been approved in Italy and Austria as a treatment for alcohol 
dependence (Alcover®, CT San Remo Pharmaceuticals)  [19], 
this compound has also shown addictive properties, raising 
questions about its safety in the treatment of alcoholic patients.
1.3	 Gamma-hydroxybutyric	acid
1.3.1 Chemical profile and neurobiology
GHB is a short-chain 4-carbon fatty acid found endogenously 
in various mammalian cerebral areas, in particular in the 
hypothalamus and basal ganglia  [20]. The primary precursor 
of GHB in the brain is GABA. GHB is formed in the brain 
from GABA-derived succinic semialdehyde (SSA) via a specific 
succinic semialdehyde reductase (SSR). GHB can be reconverted 
back to SSA via a GHB dehydrogenase, and the GHB-derived 
SSA can be converted back to GABA. SSA can also be 
metabolized by succinic semialdehyde dehydrogenase (SSADH) 
to succinic acid  [21].
Gamma-hydroxybutyric properties indicate that this 
compound might play a role in the brain as a neurotransmitter 
or neuromodulator  [22]. For example, there is evidence that 
GHB might have GABA-mimetic effects in vivo  [23]. GABAB 
receptors might play a greater role than GABAA receptors 
in mediating the effects of GHB  [24]. In particular, GHB 
might act at GABAB receptors both directly as a partial 
agonist and indirectly through GHB-derived GABA  [21]. In 
1982, Benavides et al. first described specific binding sites 
for GHB in the brain of rats  [25]. These binding sites are 
distributed in the brain of several mammals. For example, a high 
density has been found in areas such as the hippocampus and 
cortex, while a lower density exists in the cerebellum  [26]. More 
recently, a GHB receptor has been cloned and characterized in 
both rat  [27] and human  [28] brain.
GHB receptors have large functional (and probably structural) 
homologies with the GABAB receptors. However, GHB 
receptors are able to bind GHB and some structurally related 
analogs, but not GABA  [29]. Although GHB binding sites 
have been described, the exact mechanism of action of GHB 
remains elusive owing, in part, to apparent GABA-mediated 
effects  [30,31].
A part of the well-known GABA-mimetic effects, GHB 
may also work on several other neurotransmitters. For example, 
systemic administration of low doses of GHB in the rat 
inhibits burst activity and modulates firing of the dopaminergic 
terminals. With increased GHB concentrations, the initial 
decline of the dopamine release is followed rapidly by a tissue 
accumulation of dopamine in the rat brain  [32]. Additionally, 
in vivo and in vitro experiments demonstrate that GHB 
could influence the serotonergic activity in the brain, 
directly or indirectly, via an interaction with other systems 
(e.g., dopamine, GABA)  [32]. In particular, higher doses of 
GHB in rats induce an increase of the serotonin turnover in 
the striatum and mesolimbic areas. Furthermore, at high 
doses, GHB increases the release of endogenous opiates like 
donorphin and beta-endorphin in rats, although GHB does 
not seem to be a direct opiate receptor agonist  [32]. GHB 
is also able to induce a reduction of the hippocampal 
acetylcholine release by the involvement of GABAB 
receptors  [33].
1.3.2 Clinical indications
Gamma-hydroxybutyrate was identified and synthesized 
more than 40 years ago  [34]. GHB was first developed as 
a central nervous system depressant  [35] and used as an 
anesthetic adjuvant for minor surgical procedures in laboratory 
as well as in clinical settings  [36-38]. The use of GHB as an 
anesthetic is now decreasing, although it is still approved in 
Germany for intravenous anesthesia  [24].
In the 1970s, GHB was found to be effective in the treatment 
of narcolepsy  [39,40]. In particular, nightly doses of GHB 
were shown to improve the structure of sleep in narcoleptic 
patients, reducing the number of nocturnal awakenings and 
daytime attacks of cataplexy  [41]. In the USA, Canada, the 
European Union and Switzerland, GHB is now designed as 
orphan drug status for the treatment of narcolepsy (Xyrem®, 
Jazz Pharmaceuticals, Inc., Valeant Pharmaceuticals 
International, and UCB). In particular, in the USA, through 
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(Xyrem®) as a schedule III controlled substance to treat a 
small subset of patients with narcolepsy who have episodes 





There is an increasing interest in investigating non- 
benzodiazepine GABAergic compounds in the treatment of 
alcohol withdrawal syndrome (AWS) (see  [42]).
The rationale for testing GHB as a pharmacological 
compound in the treatment of AWS is the alcohol-mimicking 
profile of GHB in the central nervous system  [43]. In animals, 
GHB can suppress ethanol withdrawal syndrome in alcohol-
dependent animals  [44,45]. In terms of mechanism of action, 
the close similarity of the pharmacological profiles of GHB 
and alcohol has led to the hypothesis that GHB works as a 
‘substitution’ of alcohol in the central nervous system  [44,46,47].
Consistent with animal data, clinical studies demonstrated 
the efficacy of GHB in reducing symptoms of AWS. In 
particular, Gallimberti et al.  [48] did a small, randomized, 
double-blind study showing that GHB (50 mg/kg t.i.d.) was 
able to reduce withdrawal symptoms. More recently, the 
efficacy of GHB (50 mg/kg in 3 divided doses) has been 
successfully demonstrated in a larger sample of inpatients 
who developed AWS symptoms after being admitted to 
different clinical settings (e.g., psychiatry, internal medicine, 
surgery)  [49].
Three studies have compared GHB versus other 
pharmacotherapies for AWS. The first study compared GHB 
(50 mg/kg in 3 divided doses) with diazepam over 
10 days  [50]. The Clinical Institute Withdrawal Assessment 
for Alcohol Scale – revised (CIWA-Ar  [51]) was used to 
assess the severity of AWS symptoms. The diazepam dose 
was 0.5 – 0.75 mg/kg body weight for the first 6 days; from 
the 7th day on, diazepam was reduced at least 25% daily 
and stopped on day 10  [50]. This single-blind comparative 
study showed no significant difference between the two 
groups receiving either GHB or diazepam in CIWA-Ar total 
score at baseline and at subsequent observations. Therefore, 
this study indicated that GHB might be effective as the 
‘gold standard’ diazepam in the treatment of AWS. Interestingly, 
among CIWA-Ar subscores a significant reduction in mean 
score of anxiety on day 4 and of agitation on day 5 was 
observed in the GHB group with respect to the diazepam 
group, suggesting a more prompt effect of GHB in reducing 
these symptoms  [50]. More recently, this comparative study was 
replicated by Nava et al.  [52] in 42 inpatients affected by severe 
AWS. The patients were treated with GHB (50 mg/kg/day 
q.i.d.) or diazepam (0.5 mg/kg/day q.i.d.) for 3 weeks using 
an open-label design. This study demonstrated that GHB was 
more effective than diazepam in reducing both CIWA-Ar total 
score and CIWA-Ar mean subscores (tremor, paroxysmal 
sweats, anxiety and agitation) as well as in reducing cortisol 
levels at different observation times  [52]. Several factors could 
explain the different results between this study  [52] and the 
previous study by Addolorato et al.  [50]. These factors include 
the difference in the frequency of GHB administration, 
different diazepam dosage and daily administration, 
study design and age and duration of alcoholism of the 
patients enrolled.
A double-blind study was designed by Nimmerrichter 
et al.  [53] to assess two doses of GHB (50 or 100 mg/kg in 
3 divided doses) compared with clomethiazole in the treatment 
of AWS. The results indicate no difference between the three 
treatment arms and no increase in withdrawal symptoms after 
tapering off the medications  [53].
In each of these trials  [48-50,52,53], no serious side effects 
were reported. Mild side effects included vertigo, drowsiness, 
dizziness, rhinitis, diarrhea and nausea. Moreover, the results 
reported by Nimmerrichter et al.  [53] indicate that the lower 
dose of 50 mg/kg proved sufficient in the treatment of 
severe AWS since no difference was demonstrated between 
the two GHB-treated groups. Additionally, more frequent 
side effects (especially vertigo and diarrhea) were reported in 
the group treated by GHB 100 mg/kg  [53].
2.2	 GHB	as	an	anti-craving	drug	in	the	treatment	of	
alcohol	dependence
The central role of GHB in modulating the activity of 
dopamine, serotonin, acetylcholine, opioids and GABA  [20,54] 
led to the suggestion that GHB plays a role in reducing 
alcohol craving and alcohol consumption. Consistent with 
this rationale, GHB has been shown capable of inhibiting 
voluntary ethanol consumption in rats with ethanol 
preference  [44,47,55].
In humans, GHB has been shown to reduce alcohol 
craving, promoting short-term  [56] and medium-term  [57,58] 
alcohol abstinence in alcoholic patients. In particular, 
Gallimberti et al.  [56] carried out a randomized, double-blind 
study treating patients with GHB at dose of 50 mg/kg 
(divided into 3 daily doses) or placebo for 3 months. Compared 
with placebo, GHB was significantly superior in increasing 
the number of abstinent days, in reducing the number of 
daily drinks and in reducing alcohol craving  [56].
A multicenter study investigated the efficacy, safety and 
tolerability of GHB in the treatment of alcohol dependence 
after a longer administration of GHB (6 months)  [57] and 
using a longer follow-up of 1 year  [58]. The study demon-
strated GHB efficacy in reducing alcohol craving and in 
improving the abstinence rate. Moreover, GHB proved to 
be manageable, with few side effects, such as dizziness, 
sleepiness and tiredness, usually present only during the 
first 2 – 3 weeks of treatment with GHB.
In spite of the possible utility of GHB in inducing 
short-term  [56] and medium-term  [57,58] alcohol abstinence, 
about 30 – 40% of alcoholic participants were not totally 

















































































































patients not totally abstinent from alcohol sometimes 
described a temporary reduction of alcohol craving during 
the day but not enough to control completely their desire to 
drink alcohol during the entire day. This clinical observation 
led Addolorato and colleagues to hypothesize that those 
subjects might benefit from a greater fractioning of the same 
dose of GHB, therefore without increasing the dose of 
50 mg/kg tested in the first study. This hypothesis was also 
supported by human laboratory studies showing the short 
half-life of GHB  [59].
In order to test this hypothesis, a study was conducted, 
investigating the administration of GHB six times a day in 
subjects not totally alcohol abstinent after a previous 
treatment with GHB administered three times a day  [60,61]. 
This study demonstrated the ability of GHB administered 
six times a day in promoting abstinence in a great percentage 
of those subjects not totally abstinent from alcohol 
after treatment with GHB administered three times a 
day. These results were consistent with the hypothesis 
that a greater fractioning of the same dose of GHB (50 mg/kg) 
could induce a significant reduction of alcohol craving 
and intake.
More recently, a 1-year, open-label study tested the efficacy 
of GHB (doses ranging between 25 and 100 mg/kg/day) in 
‘treatment-resistant’ chronic alcoholics defined as patients 
who had previously received at least two treatments with 
psychoactive drugs (i.e., selective serotonin reuptake inhibitors 
[SSRIs], mood stabilizers, tryciclics) and/or self-help group 
intervention, without achieving alcohol abstinence and/or 
with episodes of relapse (heavy drinking)  [62]. The results of 
the study showed that 60% of patients achieved a complete 
abstinence from alcohol (‘full-responders’) or at least showed 
a marked decrease of their alcohol consumption (‘partial- 
responders’)  [62]. This study showed that the retention rate 
during treatment with GHB was significantly higher than 
the retention rate of the same sample treated with previous 
pharmacotherapies. Furthermore, this study confirmed that 
the only significant predictor of the retention rate was the 
six-times-daily fractionated administration of GHB  [62], an 
observation in close agreement with the previous study by 
Addolorato et al.  [60].
Laboratory studies with healthy subjects investigated 
the effects of administering alcohol and a single dose of 
GHB 50 mg/kg together. These experiments showed 
an increased rate of side effects, probably due to the 
combination of GHB and alcohol  [63]. This effect was not 
observed in the clinical studies with alcoholics reported 
above. In fact, no side effects due to the combination 
of GHB 50 mg/kg (divided in 3 – 6 daily doses) and 
alcohol were observed in those alcoholics treated with GHB 
and still drinking during the treatment  [56,58,60,61]. It is 
conceivable that the use of the same dose of 50 mg/kg 
divided in three to six daily administrations was able to 
prevent the occurrence of unsafe effects when associated 
with ethanol  [64].
2.3	 GHB	compared	and	combined	with	other	
medications	in	the	treatment	of	alcohol	dependence
Some studies have compared GHB with other medications 
in reducing alcohol consumption and achieving alcohol 
abstinence. A 3-month randomized open-label study compared 
GHB (50 mg/kg of body weight t.i.d p.o.) versus naltrexone 
(50 mg/day p.o.) in maintaining alcohol abstinence in alcohol-
dependent subjects. This study suggested a significant higher 
effect of GHB versus naltrexone in promoting alcohol 
abstinence  [65]. However, this study also demonstrated that 
non-abstinent subjects relapsed in heavy drinking in the GHB 
group while in the naltrexone group, confirming the ability 
of naltrexone in reducing alcohol relapses. More recently, a 
12-month study compared GHB (50 mg/kg/day), naltrexone 
(50 mg/day) and disulfiram (200 mg/day) in treating 
alcohol-dependent patients. Despite a trend in favor of GHB 
being observed, this study did not show any significant 
difference across the three treatments  [66]. In these comparative 
studies, none of the patients treated with GHB developed 
craving for this drug  [65,66].
On the basis of the first comparative study, Caputo et al. 
hypothesized that the combination of GHB and naltrexone 
might work better than either drug alone in the treatment 
of alcohol-dependent patients. Therefore, a 3-month, open-label 
study was performed. Alcohol-dependent subjects were 
randomly assigned to receive GHB, naltrexone or the 
combination of GHB and naltrexone  [67]. The same doses of 
the previous comparative study were used  [65]. The results of 
this study showed a significant higher effect of GHB and 
naltrexone combined in maintaining total alcohol abstinence 
than either GHB or naltrexone alone  [67]. Moreover, relapses 
in heavy drinking tended to occur less frequently in the 
GHB + naltrexone group than in either GHB-only or 
naltrexone-only groups. These results are consistent with the 
hypothesis that the alcohol-mimic effect of GHB and the 
anti-reward properties of naltrexone work synergistically and 
that naltrexone may modulate GHB actions in alcoholics 
(Figure 1). Furthermore, no patients developed craving for 
GHB in the group treated with GHB + naltrexone. On the 
contrary, 10% of those subjects treated with GHB alone 
developed craving for GHB  [67]. This observation is consistent 
with a previous observation by Caputo et al.  [68] and may 
indicate that the anti-reward properties of naltrexone may be 
able to avoid the development of craving for GHB (Figure 1).
More recently, a 6-month, open-label study compared 
groups of alcohol-dependent patients randomly assigned to 
receive escitalopram, escitalopram + GHB, escitalopram + 
naltrexone, or escitalopram + GHB + naltrexone  [69]. In this 
study, the combination of escitalopram + GHB + naltrexone 
resulted to be more useful in preventing alcohol relapses 
than GHB + escitalopram, naltrexone + escitalopram or 
escitalopram given alone  [69]. These results are consistent 
with the notion that there are different craving profiles 
(i.e., reward, relief, obsessive) and with the hypothesis that 
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As a consequence, the combination of different classes of 
medications, such as GHB, naltrexone and escitalopram 




The identification of alcohol-dependent subtypes may assist 
in the ascertainment criteria for clinical trials performed in 
behavioral and pharmacological interventions  [70,71]. As 
reported in detail in the section 3, craving for GHB and 
abuse of GHB represent crucial aspects during the use of 
this drug in treating alcohol-dependent patients. Therefore, 
it is of paramount importance to investigate ways to develop 
better manageability and safety of GHB in alcohol-dependent 
individuals. For example, the identification of subgroups of 
alcoholics more predisposed to develop this unfavorable 
effect is important. A recent study investigated the risk of 
developing craving for and abuse of GHB among different 
groups of alcoholics  [72]. In this study, 47 alcohol-dependent 
patients were enrolled and treated with GHB orally admin-
istered (50 mg/kg of body weight t.i.d.) for 3 months. At 
the end of the study, the utility of GHB in promoting alcohol 
abstinence in the whole sample analyzed was confirmed. 
Craving for GHB was significantly higher in those alcoholics 
with previous cocaine dependence than in ‘pure’ alcoholics 
(‘pure’ alcoholics were defined as those patients with a diagnosis 
of alcohol dependence without other addictive disorders)  [72]. 
Moreover, craving for GHB did not differ between ‘pure’ 
alcoholics and alcoholics with opioid dependence in remis-
sion. However, all alcoholics with opioid dependence in 
remission abused GHB. On the contrary, none of the ‘pure’ 
alcoholics abused GHB. In summary, this study suggests 
that the administration of GHB is not recommended in those 
alcoholics with a diagnosis of opioid or cocaine dependence, 
even if in sustained full remission.
3.	 Risk	of	GHB	abuse	and	dependence
As mentioned above, GHB was approved for alcohol 
dependence in Italy and Austria. However, there are also 
some concerns about the use of this medication in an 
addicted population, since the addictive properties of GHB, 
potential of GHB abuse and/or dependence are related to its 
neurobiology. The intrinsic neurobiological activity of GHB 
might be mediated through the GABAB receptor and the 
GHB receptor. Studies in vitro have demonstrated that chronic 















alcoholic	patients. The alcohol-mimic effect of GHB and the anti-reward properties of NTX may work synergistically in reducing alcohol 
consumption, therefore promoting alcohol abstinence. Furthermore, the anti-reward action of NTX may be able to avoid the development 
of craving for GHB.



















































thus reducing their ability to inhibit neurotransmitter 
release. Under conditions of chronic GHB intake, it is possible 
that compensatory mechanisms may occur that offset the 
inhibition of dopamine release, resulting in an increase 
of dopamine, GABA and/or glutamate release  [21]. This 
scenario could contribute to the addictive properties of 
GHB. Addictive properties of GHB have been observed in 
both non-alcoholics and alcoholics. However, important 
differences exist between the use of GHB as a therapeutic 
option to treat alcohol-dependent subjects and the illegal 
use and abuse of GHB in non-alcoholics (see Table 1).
3.1	 GHB	abuse	and	dependence	in	non	alcoholics
GHB’s action as a depressant of the central nervous system 
is in some ways similar to those of classical sedative hypnotics 
such as barbiturates and benzodiazepines. On the basis of 
these properties, GHB has been used to treat insomnia  [73]. 
On the other hand, GHB plays a role as a euphoriant. 
GHB’s euphoria-inducing effect has made it popular as a 
recreational drug  [74] in the USA and UK, where it is sold 
clandestinely mostly on the street  [75], at ‘rave’ parties  [76], in 
nightclubs  [77] and on internet sites  [78] under the names of 
‘liquid ecstasy’, ‘liquid X’, ‘Georgia Home Boy’, ‘Grievous 
Bodily Harm’, ‘Soap’, ‘Cherry Menth’, ‘G-Riffick’, ‘Salty 
Water’, among others  [79]. GHB has become a widespread 
drug of abuse in the USA since the 1980s. More recently, 
the recreational use of GHB has become popular in Europe 
as well  [80].
In the spring of 1990, GHB appeared in the USA on the 
commercial market as a health food product to promote 
‘natural sleep’ and weight loss. Moreover, GHB has been 
widely used in the body-building community because of its 
ability to promote muscle growth and decrease body 
fat  [73,81]. GHB has been shown to stimulate the release of 
human growth hormone (GH) from the anterior pituitary  [78]. 
However, in alcoholics there is no evidence that the short-term 
elevations in GH produced by GHB result in any increase 
in muscle mass  [82].
The steep dose–response curve of GHB means that 
overdosing easily occurs, in particular when inaccurate and 
unknown doses of GHB are consumed, as in the case of 
GHB illegally sold on the streets  [80]. As a consequence, in 
the last decades, cases of GHB toxicity have increased at 
hospital emergency departments. For example, a Swiss study 
reported that GHB accounted for 12.5% of intoxications at 
emergency departments in 2001, rising to 27.2% by 
2003  [83]. Deaths from GHB use have been reported in the 
UK and elsewhere  [84].
Signs and symptoms of GHB poisoning have been 
reported at doses of < 2.5 – 30 g. Adverse effects included 
dizziness, nausea, vomiting, myoclonic muscle movements (jerks), 
agitation, confusion, hallucinations, loss of peripheral vision 
and delirium. As a result of the high incidence of vomiting 
(> 50%), there is also a risk of pulmonary aspiration  [85]. Doses 
higher than 10 – 20 g can decrease cardiac output and 
produce severe respiratory depression, seizure-like activity and 
coma  [75,77,86]. No specific antidotes are available for the treat-
ment of GHB intoxication. As a consequence, the acute med-
ical treatment is only supportive. Some uncontrolled clinical 
studies have suggested that opioid antagonists such as naloxone 
may be effective on GHB intoxication, although the study 
design does not allow definitive conclusions to be drawn  [80].
In some individuals, repeated and persistent use of GHB 
may lead to the development of physical dependence  [80], 
including the presence of withdrawal. For example, the 
California Poison Control System recorded 30 cases of with-
drawal from 356 GHB exposures in 1999 and an internet 
help site on GHB recorded 184 cases of withdrawal across 
33 US states by 2001  [87]. GHB withdrawal may include 
symptoms such as anxiety, insomnia and tremor. The clinical 
picture can rapidly deteriorate into delirium, hallucinations 
and/or psychosis. GHB withdrawal may require either an 
outpatient or inpatient treatment with benzodiazepines, 
depending on the severity of the symptoms. In particular, 
benzodiazepines represent the recommended treatment, 
though cases of GHB withdrawal unsuccessfully treated with 
benzodiazepines have been reported  [88]. By November 1990, 
in the USA, 57 cases of GHB poisoning and related illnesses 
such as seizures and comas were reported in nine states  [73,89]. 
The FDA issued a ban, removing GHB from the market. 
Because of its abuse potential, in the USA, GHB was 
classified as a schedule I controlled substance in 2000. As 
mentioned above, GHB is at present approved by the FDA 
as a schedule III drug only for the treatment of patients 
with narcolepsy who have episodes of weak or paralyzed 
muscles (i.e., cataplexy)  [90].
3.2	 GHB	abuse	and	dependence	in	alcoholics
A survey analysis indicated that GHB has been administered 
orally as a maintenance treatment to 732 alcohol-dependent 
outpatients (50 – 100 mg/kg/day divided in 3 or more 
doses) for 132.2 ± 57.9 days  [19]. These patients also attended 
supportive psychosocial programs, and the administration of 
GHB was entrusted to a family member. A percentage of 
these patients (varying according to the different reports 
from 2.6 to 10.1%) showed craving for the drug and 
increased the dosage (up to 6 – 7 times the recommended 
dose)  [19,58,91].
Interestingly, Addolorato et al.  [58] first reported the risk of 
GHB abuse in alcohol-dependent patients treated with GHB. 
However, a greater fractioning of the same dose of GHB was 
able not only to decrease alcohol craving and alcohol intake 
but also to reduce the incidence of GHB abuse  [60,61]. Further-
more, in 1999 the first case of GHB dependence with 
withdrawal symptoms was reported in a woman treated 
with GHB for alcohol dependence  [92]. In this report, GHB 
withdrawal syndrome was characterized by high anxiety levels, 
tremor, sweating, nausea without vomiting and tachycardia. 
Total regression of withdrawal symptoms was obtained 
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We also note that the medium therapeutic dose of GHB 
in alcoholics is about five times lower than the minimum 
daily dose of GHB associated with withdrawal  [93,94]. 
In addition, GHB withdrawal is usually present in those 
cases of nonclinical and self-administered prolonged abuse of 
GHB  [95]. In alcoholics, withdrawal and physical depen-
dence do not appear when GHB, used at therapeutic dosage, 
is discontinued.
In conclusion, GHB abuse and dependence during treatment 
for alcohol dependence is a limited phenomenon  [78]. However, 
this risk remains an important concern, especially considering 
the use of GHB in an addicted population. Given the 
potential for abuse, GHB is not recommended to treat alcohol 
dependence, at least in those countries like the USA, where 
GHB is a schedule III controlled substance  [90]. Furthermore, 
the use of GHB as a treatment for alcohol dependence 
requires caution, also in those countries where GHB is 
approved for alcohol dependence. A greater fractioning of 
the dose of GHB is strongly recommended  [60]. Nevertheless, 
the use of GHB in alcohol dependence deserves further 
investigation, in particular considering the possibility of 
combining GHB with other medications (see section 2.3) as 
well as the possibility of identifying possible alcoholic subtypes 
better responding to GHB treatment (see section 2.4).
4.	 GHB,	GABA	system	and	alcohol	
dependence:	how	to	move	forward?
The clinical studies reported in the present review show the 
therapeutic potential of GHB for alcohol dependence. In 
particular, these studies suggest that GHB may be useful in 
treating AWS as well as in the long-term aim to achieve and 
maintain abstinence from alcohol.
However, studies on a greater number of patients are 
needed. For example, further comparative studies between 
GHB and benzodiazepines are needed to test the role of 
GHB as a treatment for AWS. The studies available until 
now present some limits, such as the different settings 
(e.g., inpatients vs outpatients) and the enrolment of patients 
with different severities of AWS. Furthermore, there are no 
data on the possible efficacy of GHB in more complicated 
forms of AWS, including seizures and delirium tremens. At 
present, benzodiazepines represent the gold standard in the 
treatment of AWS, in particular considering their ability 
both to prevent and treat the more serious complications, 
such as seizures and delirium tremens  [42].
The ability of GHB to reduce alcohol craving and intake 
suggests that this drug may be useful in the long-term 
treatment of alcohol-dependent subjects. Also in this case, 
however, studies with a greater number of patients and 
with longer follow-up periods are needed. Recent research 
also points to the possible benefits of combining medications 
acting on different neurobiological targets. The combination 
of GHB and naltrexone is of interest because these two 
drugs work on several neurotransmitter circuits. For example, 
a possible future approach could be to investigate the role 
of naltrexone in those GHB-treated alcoholics who relapsed 
and/or developed a craving for GHB. Despite the small 
sample, the study combining GHB and naltrexone 
(see  [67]) demonstrated the safety of this combination and 





Side-effects Mild side effects, such as vertigo, 
drowsiness, dizziness, rhinitis,  
diarrhea, nausea, sleepiness
Mild and severe side effects, such as dizziness, nausea, 
vomiting (with risk of pulmonary aspiration), myoclonic 
muscle movements (jerks), agitation, confusion, 
hallucinations, loss of peripheral vision, delirium.
Doses higher than 10 – 20 g can also decrease cardiac 
output and produce severe respiratory depression,  
seizures and coma
Anabolic effect with increased 
growth hormone (GH) release
Absent Present
GHB physical dependence Rare Possible
Formulation Standardized controlled  
concentrations
Inaccurate and greatly variable concentrations
Manufacturer Synthesized by pharmaceutical  
industries
Synthesized by illegal laboratories
Availability Only prescribed by specialized  
physicians in those countries where  
GHB is approved as a treatment  
for alcohol dependence
Sold clandestinely in several Countries, especially in  


































































As noted in the Introduction, there is an increasing interest 
in studying the role of GABAergic medications in alcohol 
dependence  [18] (i.e., topiramate  [96], baclofen  [97] and 
gabapentin  [98]). Therefore, it will be of interest to carry out 
studies comparing and/or combining GHB with other 
GABAergic medications.
The risk of GHB abuse underlines the need to develop 
valuable ways to reduce this risk when GHB is used as a 
therapeutic option for alcohol dependence. From this 
prospective, the recent study by Caputo et al.  [72] indicates 
that GHB should not be administered to those alcohol- 
dependent individuals with history of either cocaine or 
opioid dependence. Future studies will have to continue this 
approach, trying to identify alcoholic subtypes with a higher 
response to GHB treatment but with a lesser risk of GHB 
abuse. This approach may include: i) the application of 
typology classifications (i.e., early- vs late-onset alcoholics, 
Cloninger typologies, Babor typologies, and many others; 
see  [71]); ii) the application of intermediate phenotypes – or 
endophenotypes – to generate more homogeneous diagnostic 
groupings (see  [99]); and iii) the identification of biological 
markers (i.e., genetic polymorphisms of the GABA receptor; 
see  [100]) that may predict response to GHB treatment.
5.	 Expert	opinion
Gamma-hydroxybutyric acid (GHB) has been proposed as a 
possible medication in the treatment of alcohol dependence. 
Although further studies are needed to confirm GHB efficacy 
in larger samples, the studies available demonstrate that GHB 
appears to be effective both in the management of AWS and 
in the maintenance of long-term abstinence  [48-50,52,53,56-62]. 
GHB has also obtained regular approval for alcohol dependence 
in some European countries.
In the USA as well as in Europe, however, there has 
been increasing attention to the risk of GHB abuse and 
dependence. The recreational use of GHB is a serious 
problem, also considering the possible use of high 
doses with the consequent risk of toxicity. Moreover, the 
chronic abuse of GHB may lead to the development of 
GHB dependence.
GHB abuse seems a limited phenomenon when GHB is 
used at therapeutic doses to treat alcohol-dependent patients. 
However, cases of craving for GHB with consequent abuse 
of the drug and possible dependence may occur during its 
use to treat alcohol dependence. This feature strongly suggests 
that GHB must be used under strict medical surveillance 
and with a multidisciplinary approach that includes a sup-
portive psychosocial program and the cooperation of a family 
member. Only physicians with experience in administering 
GHB to alcoholics should use this medication to treat 
alcohol dependence.
Finally, recent studies suggest the usefulness of combining 
GHB with naltrexone in treating alcohol-dependent subjects 
as well as the possible identification of alcohol-dependent 
subtypes at lower risk of developing GHB abuse. These 
studies provide the basis for future research whose goal will 
be to investigate an efficacious and safe use of GHB in the 
management of alcohol-dependent patients.
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